desonide and Dermatitis--Contact

22 cases of allergic contact dermatitis from topical corticosteroids were observed in Strasbourg and previously published. 7 further cases are reported here and the vehicle and concentration of corticosteroids for patch tests are discussed. A 0.1% concentration in petrolatum seemed adequate for testing the 4 molecules (triamcinolone acetonide, dexamethasone, desonide and amcinonide) responsible for the 7 new cases. In 1 case, several cross-reactions were seen. A corticosteroid screening series permits patch testing of the suspected molecule(s) in a selective way. Without this series, long delays are required to make the correct diagnosis by patch testing. We have reviewed more than 60 papers on corticosteroid allergy published up to now.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dermatitis, Contact; Desonide; Dexamethasone; Drug Eruptions; Female; Glucocorticoids; Humans; Male; Middle Aged; Patch Tests; Triamcinolone; Triamcinolone Acetonide

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Contact; Desonide; Double-Blind Method; Drug Evaluation; Female; Humans; Hydrocortisone; Male; Middle Aged; Pregnadienetriols

Desonide, a nonfluorinated topical corticosteriod, was compared with fluocinonide, a potent fluorinated steroid, in identical concentrations, in the treatment of various steroid-responsive dermatologic disorders. In treatment comparisons, the group treated with desonide showed significantly (p less than 0.05) better erythema and scaling scores after the first week than did those in the fluocinonide group, but the two week scores were not significantly different. Although 5 percent of patients treated with fluocinonide had adverse reactions, no such reactions were observed in the desonide-treated group.

Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Contact; Desonide; Female; Fluocinolone Acetonide; Fluocinonide; Humans; Infant; Male; Middle Aged; Pregnadienetriols; Skin Diseases; Time Factors

Our group previously reported the photoinstability of some desonide topical commercial formulations under direct exposure to UVA radiation.. This study aimed to prepare and characterize a gel-cream containing desonide, with greater photostability than the commercial gel-cream (C-GC). Benzophenone-3 (BP-3) was used as a photostabilizing agent.. The gel-cream developed (D-GC) containing BP-3 at 0.1% was prepared and characterized regarding its pH, drug content, spreadability, viscosity, in vitro drug release and in vitro permeation. The in vivo anti-inflammatory effect was assessed by ear edema measurement, croton oil-induced acute skin inflammation and myeloperoxidase assay.. D-GC presented characteristics compatible with topical application, appropriate drug content and good spreadability, and non-Newtonian behavior with pseudoplastic flow. D-GC showed a good photostability profile, presenting a desonide content of 95.70% after 48 h of exposure to UVA radiation, and stability under room conditions during 60 days. The amount of desonide released from D-GC and C-GC was 57.8 and 51.7 µg/cm. D-GC represents a promising approach to treat dermatological disorders, since it presented satisfactory physicochemical characteristics, the same biological activity as C-GC and superior photostability, conferred by the addition of BP-3 at 0.1%.

Topics: Animals; Anti-Inflammatory Agents; Benzophenones; Chemistry, Pharmaceutical; Croton Oil; Dermatitis, Contact; Dermatologic Agents; Desonide; Disease Models, Animal; Ear; Gels; Glucocorticoids; Humans; Male; Mice; Skin; Skin Cream; Ultraviolet Rays

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Budesonide; Dermatitis, Contact; Desonide; Female; Glucocorticoids; Humans; Pregnenediones

The ratios of antiinflammatory activity after oral administration (oral ED50/cutaneous ED50) for desonide (Locapred) and hydrocortisone (hydrocortisone acetate) were compared in various nonimmunological and immunological experimental models on mouse ears: edema induced by croton oil; primary irritation due to picryl chloride; the acute phase (6 h) and the beginning of the chronic phase (24 h) of inflammation due to cantharidin; delayed contact hypersensitivity to picryl chloride; and the semi-delayed (6 h) and delayed (24 h) phases of contact hypersensitivity to oxazolone. These investigations showed that, besides having a better antiinflammatory effect, desonide had a better ratio of local activity to systemic effect in all the models. In addition, by contrast with orally active doses, locally active doses did not induce any thymolytic effect. Such results were confirmed in rats in which desonide reduced 24 h carrageenin abscess after cutaneous application without any significant thymolytic effect. Hydrocortisone was inactive.

Topics: Abscess; Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Carrageenan; Dermatitis, Contact; Desonide; Hydrocortisone; Leukocyte Count; Male; Mice; Organ Size; Pregnadienetriols; Rats; Rats, Inbred Strains; Thymus Gland

Topics: Adult; Dermatitis, Contact; Desonide; Drug Eruptions; Female; Groin; Humans; Intertrigo; Ointments; Patch Tests; Pregnadienetriols